Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 200mg | $275.00$150.00 | $0.75/mg | In stock | Jul 7 |
| vial | 500mg | $550.00$335.00 | $0.67/mg | In stock | Jul 7 |
| vial | 1000mg | $1320.00$550.00 | $0.55/mg | In stock | Jul 7 |
| vial | 2000mg | $2625.00$900.00 | $0.45/mg | In stock | Jul 7 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. GHK-Cu is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Peptide Partners sell GHK-Cu?
Yes — Peptide Partners currently lists GHK-Cu in 4 variants starting at $900.00 ($0.45/mg).
Is Peptide Partners's GHK-Cu third-party tested?
Yes — Disclosed Labs has indexed 4 Certificates of Analysis for Peptide Partners's GHK-Cu, with the most recent showing 99.8% purity. Peptide Partners holds an overall trust grade of A (91/100) across all 106 COAs on file.
What is Peptide Partners's trust grade for GHK-Cu?
Peptide Partners has an overall Disclosed Labs trust grade of A (91/100), computed from 106 COAs across all peptides. The most recent GHK-Cu COA was issued by BioRegen.
Where is the cheapest GHK-Cu?
As of the latest data, Sunrise Bioresearch offers GHK-Cu at $0.09/mg — compare with Peptide Partners's listing at $0.45/mg. See the full GHK-Cu price comparison.
Is GHK-Cu legal to buy?
GHK-Cu is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| CU20250717 | Aug 2025 | 99.7% | BioRegen | Endotoxin, Heavy metals | Confirmed | View |
| CU202605 | — | 99.6% | TrustPointe Analytics | Endotoxin, Sterility, Heavy metals | Confirmed | View |
| CU202604 | — | 99.9% | Kovera Labs | Endotoxin, Sterility | Confirmed | View |